Fig. 6: CONPs synergized with gemcitabine (GEM) in vivo. | Cell Death & Disease

Fig. 6: CONPs synergized with gemcitabine (GEM) in vivo.

From: Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer

Fig. 6: CONPs synergized with gemcitabine (GEM) in vivo.

a Tumor growth curve of subcutaneous nude mouse models established by implantation of T24 cells. Tumors grew more slowly in all treatment groups relative to the control group. The median survival of control, CONPs, GEM, and combination treatment groups was 20, 34, 40, and 50 days (P < 0.05; control vs CONPs, P = 0.0017; CONPs+GEM vs GEM, P = 0.0264, n = 6), respectively. b No obvious effect on body weight was observed after either single drug or combination drug administration in the treatment groups at day-20 (P > 0.05). The body weights of mice in the GEM group gradually decreased owing to increased tumor burden, and they were promptly euthanized when losses in body weight reached > 20% of baseline. c Representative images of TUNEL staining of dissected subcutaneous tumors 3 days after drug treatment in each group revealed that the drug treatment groups induced more obvious apoptosis than the control group. d Representative images of Ki-67 expression 3 days after drug treatment. Ki-67 expression decreased markedly in all treatment groups compared with the control group.

Back to article page